Eli Lilly and Company

Almudena Rubio

Jolie Anne Bastian

Daniel Jon Sall

Jeffrey Daniel Cohen

James Robert Henry

Gaiying Zhao

Jennifer Anne McMahon

William Thomas McMillen

Erik James Hembre, Ii

Christopher Stanley Galka

Maria Angeles Martinez-Grau

Nicholas Allan Honigschmidt

Gema Ruano Plaza

Jiehao Chen

Bradley Earl Reaman

Michael J Rodriguez

Jeffry Bernard Franciskovich

Deqi Guo

Richard Duane Johnston

Daryl Lynn Smith

Joshua Ryan Clayton

Douglas Linn Gernert

David Anthony Barda

Jason Eric Lamar

Mohammad Sadegh Zia-Ebrahimi

Kelly Wayne Furness

Chong Si

Santiago Carballares Martin

Sonia Maria Gutierrez Sanfeliciano

Stacy Jo Keding

Pablo Garcia Losada

Spencer Brian Jones

Wenceslao Lumeras Amador

Tao Liu

Isabel Rojo

Adam Marc Levinson

Matthew Patrick Baumgartner

Mario Barberis

Victoriano Molero Florez

Maria Lourdes Prieto Vallejo

Jennifer Anne Mcmahon

Michael John Rodriguez

William Thomas Mcmillen

Mohammed Sadegh Zia-Ebrahimi

Curren Tapfuma Mbofana

The present invention provides compounds of the formula:

KRas inhibitors

Novel selective estrogen receptor degraders (SERDs) according to the formula: pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof, wherein either Ror Ris independently selected from Cl, F, —CF, or —CH, and the other is hydrogen, and methods for their use are provided.

Selective estrogen receptor degraders

Novel selective estrogen receptor degraders (SERDs) according to the formula: pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof, wherein either Ror Ris independently selected from Cl, F, &#x2014;CF, or &#x2014;CH, and the other is hydrogen, and methods for their use are provided.

The present invention relates to certain novel 2,3-dihydro-1H-indole compounds, pharmaceutical compositions comprising the compounds, and methods of using the compounds to treat cancer, more particularly for the treatment of cancer selected from the group consisting of melanoma, acute myeloid leukemia, chronic lymphocytic leukemia, colorectal cancer, breast cancer, lung cancer, ovarian cancer, fallopian tube carcinoma, primary peritoneal carcinoma, cervical cancer, gastric cancer, liver cancer, pancreatic cancer, thyroid cancer, glioblastoma, non-Hodgkin's lymphoma, and Hodgkin's lymphoma. 

1-tetrahydropyranylcarbonyl-2,3-dihydro-1H-indole compounds for treating cancer

The present invention provides novel GOAT inhibitors and their salts and pharmaceutical compositions thereof.

Ghrelin 0-acyl transferase inhibitors

Ghrelin O-acyl transferase inhibitors

The present invention relates to certain novel 2,3-dihydro-1H-indole compounds, pharmaceutical compositions comprising the compounds, and methods of using the compounds to treat cancer, more particularly for the treatment of cancer selected from the group consisting of melanoma, acute myeloid leukemia, chronic lymphocytic leukemia, colorectal cancer, breast cancer, lung cancer, ovarian cancer, fallopian tube carcinoma, primary peritoneal carcinoma, cervical cancer, gastric cancer, liver cancer, pancreatic cancer, thyroid cancer, glioma, non-Hodgkin's lymphoma, and Hodgkin's lymphoma.

2,3-dihydro-1H-indole compounds

Growing community of inventors

Carmel, IN, United States of America

Almudena Rubio